Clostridium difficile: Progress and challenges

Annals of the New York Academy of Sciences

Volumn 1213, Issue 1, 2010, Pages 62-69

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic associated colitis; C. difficile; Clostridium difficile; Epidemiology; Fluoroquinolones; New guidelines, tests, and treatments; Oral vancomycin; Pseudomenbraneous colitis

Indexed keywords

BACITRACIN; FUSIDIC ACID; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; FATALITY; HUMAN; INCIDENCE; INFECTION RISK; POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

CLOSTRIDIUM DIFFICILE;

EID: 78650343594     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05863.x     Document Type: Article

References (83)

1. Bartlett, J.G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145: 758-764.
2. Pépin, J., L. Valiquette, M.E. Alary et al. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern disease severity. CMAJ 17: 466-472.
3. McDonald, L.C., G.E. Killgore, A. Thompson et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353: 2433-2441.
4. Cohen, S.H., D.N. Gerding, S. Johnson et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control. Hosp. Epidemiol. 31: 431-455.
5. Aronsson, B., R. Mölby & C.E. Nord 1985. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J. Infect. Dis. 151: 476-481.
6. Rouphael, N.G., J.A. O'Donnell, J. Bhatnagar et al. 2008. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am. J. Obstet. Gynecol. 198: e1-e6.
7. Bryant, K. & L.C. McDonald 2009. Clostridium difficile infections in children. Pediatr. Infect. Dis. J. 28: 145-146.
8. Centers for Disease Control and Prevention (CDC). 2008. Surveillance for community-associated Clostridium difficile-Connecticut, 2006. MMWR. Morb. Mortal. Wkly. Rep. 57: 340-343.
9. Zilberberg, M.D., G.S. Tillotson & C. McDonald 2010. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg. Infect. Dis. 16: 604-609.
10. Aronsson, B., R. Möllby & C.E. Nord 1985. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J. Infect. Dis. 151: 476-481.
11. O'Connor, J.R., S. Johnson & D.N. Gerding 2009. Clostridium difficile infection caused by epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924.
12. Dial, S., A. Kezouh, S. Dascal et al. 2008. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMJ 179: 767-772.
13. Burdette, S.D. & J.M. Bernstein 2007. Does the nose know? The odiferous diagnosis of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 44: 1142.
14. Wanahita, A., E.A. Goldsmith, B.J. Marino & D.M. Musher 2003. Clostridium difficile infection in patients with unexplained leukocytosis. Am. J. Med. 115: 543-546.
15. Bhangu, A., A. Czapran, S. Bhangu & D. Pillay 2010. Optimum timing of blood tests for monitoring patients with Clostridium difficile-associated diarrhea. J. Investig. Med. 58: 621-624.
16. Lamontagne, F., A.C. Labbé, O. Haeck et al. 2007. Impact of emergency colectomy on survival of patients with fulminant Clostridum difficile colitis during an epidemic caused by a hypervirulent strain. Ann. Surg. 245: 267-272.
17. Dubberke, E.R., A.M. Butler, D.S. Yokoe et al. 2010. Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes. Infect. Control. Hosp. Epidemiol. 31: 262-268.
18. Redelings, M.D., F. Sorvillo & L. Mascola 2007. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 13: 1417-1419.
19. Denève, C., C. Janoir, I. Poilane, et al. 2009. New trends in Clostridium difficile virulence and pathogenesis. Int. J. Antimicrob. Agents. 33(Suppl. 1): S24-S28.
20. Hensgens, M.P., A. Goorhuis, D.W. Notermans et al. 2009. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro. Surveill. 14(45). Pii: 19402-19404.
21. Miller, M., D. Gravel, M. Mulvey et al. 2010. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50: 194-201.
22. O'Connor, J.R., S. Johnson & D.N. Gerding 2009. Clostridium difficile infection caused by the epidemic BI/BNAP1/027 strain. Gastroenter. 136: 1913-1924.
23. Cloud, J. & C.P. Kelly 2007. Update on Clostridium difficile associated disease. Curr. Opin. Gastroenterol. 23: 4-9.
24. Warny, M., J. Pépin, A. Fang et al. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084.
25. Verdoom, B.P., R. Orenstein, J.E. Rosenblatt, L.M. Sloan et al. 2010. High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diag. Microbiol. Infect. Dis. 66: 24-28.
26. Freeman, J., W. Fawley, S. Baines & M. Wilcox 2006. Measurement of toxin production by Clostridium difficile. Lancet 367: 982-983.
27. Denève, C., C. Janoir, I. Poilane et al. 2009. New trends in Clostridium difficile virulence and pathogenesis. Int. J. Antimicrob. Agents. 33(Suppl. 1): 24-28.
28. Chang, T.W., J.G. Bartlett & N.S. Taylor 1981. Clostridium difficile toxin. Pharmacol. Ther. 13: 441-452.
29. Taylor, N.S. & J.G. Bartlett 1979. Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev. Infect. Dis. 1: 379-385.
30. Taylor, N.S., G.M. Horne & J.G. Bartlett 1981. Comparison of two toxins produced by Clostridium difficile. Infect. Immun. 34: 1036-1043.
31. Laughon, B.E., R.P. Viscidi, S.L. Gdovin et al. 1984. Enzyme immunoassays for detection of Clostridium difficile toxins A and B fecal specimens. J. Infect. Dis. 149: 781-788.
32. Lyerly, D.M., N.M. Sullivan & T.D. Wilkins 1983. Enzyme-linked immunosorbent assay for Clostridium difficile toxin. A. J. Clin. Microbiol. 17: 72-78.
33. Schmidt, M.L. & P.H. Gilligan 2009. Clostridium difficile testing algorithms: what is practical and feasible? Anaerobe 15: 270-273.
34. Crobach, M.J., O.M. Dekkers, M.H. Wilcox & E.J. Kuijper 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin. Microbiol. Infect. 15: 1053-1066.
35. Mohan, S.S., B.P. McDermott, S. Parchuri & B.A. Cunha 2006. Lack of value of repeat stool testing for Clostridium difficile toxin. Am. J. Med. 119: e7-e8.
36. Hafiz, S. & C.L. Oakley 1976. Clostridium difficile: isolation and characteristics. J. Med. Microbiol. 9: 129-136.
37. Johnson, S., C.R. Clabots, F.V. Linn et al 1990. Nonocomial Clostridium difficile colonization and disease. Lancet 336: 97-100.
38. McFarland, L.V., M.E. Mulligan, Ry Kwok & W.E. Stamm 1989. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320: 204-210.
39. Muto, C.A. 2007. Asymptomatic Clostridium difficile colonization: is this the tip of another iceberg? Clin. Infect. Dis. 45: 999-1000.
40. Sharp, S.E., L.O. Ruden, J.C. Pohl et al. 2010. Evaluation of the C.DIFF Quik Chek Complete assay, a new GDH & A/B toxin combination lateral flow assay for use in the rapid simple diagnosis of Clostridium difficile disease. J. Clin. Micrbiol. 48: 2082-2086.
41. Quinn, C.D., S.E. Sefers, W. Babiker et al. 2010. C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J. Cin. Microbiol. 48: 603-605.
42. Kvach, Ej., D. Ferguson, P.F. Riska & M.L. Landry 2010. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J. Clin. Microbiol. 48: 109-114.
43. Peterson, L.R. & A. Robicsek 2009. Does my patient have Clostridium difficile infection? Ann. Intern. Med. 151: 179-179.
44. Stamper, P.D., R. Alcabasa, D. Aird et al. 2009. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J. Clin. Microbiol. 47: 373-378.
45. Peterson, L.R., R.U. Manson, S.M. Paule et al. 2007. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin. Infect. Dis. 45: 1152-1160.
46. Keighley, M.R., D.W. Burdon, Y. Arabi et al. 1978. Randomized controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br. Med. J. 2: 1667-1669.
47. Mogg, G.A., D.W. Burdon & M. Keighley 1979. Oral metronidazole in Clostridium difficile colitis. Br. Med. J. 2: 335.
48. Teasley, D.G., D.N. Gerding, M.M. Olson et al. 1983. Prospective randomized trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2: 1043-1046.
49. Wenisch, C., B. Parschalk, M. Hasenhündl et al. 1996. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22: 813-818.
50. Huang, H., A. Weintraub, H. Fang & C.E. Nord 2009. Antimicrobial resistance in Clostridium difficile. Int. J. Antimicrob. Agents. 34: 516-522.
51. Johnson, S., S.R. Homann, K.M. Bettin et al. 1992. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern. Med. 17: 297-302.
52. Bartlett, J.G. 2008. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin. Infect. Dis. 46: 1489-1492.
53. Bolton, R.P. & M.A. Culshaw 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27: 1169-1172.
54. Baines, S.D., R. O'Connor, J. Freeman et al. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62: 1046-1052.
55. Zar, F.A., S.R. Bakkanagari, K.M. Moorthi & M.B. Davis 2007. A comparison of vanocmycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45: 302-307.
56. Abougergi, M.S., A. Broor, W. Cui & B.G. Jaar 2010. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of literature. J. Hosp. Med. 5: E1-E9.
57. O'Horo, J. & N. Safdar 2009. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int. J. Infect. Dis. 13: 663-667.
58. Lowy, I., D.C. Molrine, B.A. Leav et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362: 197-205.
59. Pépin, J., T.T. Vo, M. Boutros et al. 2009. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis. Colon. Rectum. 52: 400-405.
60. Gash, K., E. Brown & A. Pullyblank 2010. Emergency subtotal colectomy for fulminant Clostridium difficile colitis-is a surgical solution considered for all patients? Ann. R. Coll. Surg. Engl. 92: 56-60.
61. Jaber, M.R., S. Olafsson, W.L. Fung & M.E. Reeves 2008. Clinical review of the management of fulminant Clostridium difficile infection. Am. J. Gastroenterol. 103: 3195-3203.
62. Kelly, C.P. 2009. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea. JAMA 301: 954-962.
63. Kyne, L. 2010. Clostridium difficile-beyond antibiotics. N. Engl. J. Med. 363: 264-265.
64. McFarland, L.V., G.W. Elmer & C.M. Surawicz 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97: 1769-1775.
65. Tedesco, F.J. 1982. Treatment of recurrent antibiotic-associated pseudomenbranous colitis. Am. J. Gastroenterol. 77: 220-221.
66. Bartlett, J.G. 2009. New antimicrobial agents for patients with Clostridium difficile infections. Curr. Infect. Dis. Rep. 11: 21-28.
67. Dudley, M.N., J.C. McLaughlin, G. Carrington et al. 1986. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch. Intern. Med. 146: 1101-1104.
68. De Lall, F., R. Nicolin, E. Rinaldi et al. 1992. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomenbranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents. Chemother. 36: 2192-2196.
69. Musher, D.M., N. Logan, A.M. Bressler et al. 2009. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin. Infect. Dis. 48: e41-e46.
70. Wullt, M. & I. Odenholt 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimocrob. Chemother. 54: 211-216.
71. Johnson, S., C. Schriever, U. Patel et al. 2009. Rifamaxin redux: treatment of recurrent Clostridium difficile infections with rifamaxin immediately post-vancomycin treatment. Anaerobe 15: 290-291.
72. O'Horo, J. & N. Safdar 2009. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int. J. Infect. Dis. 13: 663-667.
73. Miller, M. 2010. Fidaxomicin (OPT-80)(for the treatment of Clostridium difficile infection. Expert. Opin. Pharmacother. 11: 1569-1578.
74. Lowy, I., D.C. Molrine, B.A. Leav et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362: 197-205.
75. Weiss, K. 2009. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int. J. Antimicrob. Agents. 33: 4-7.
76. Mogg, G.A., R.H. George, D. Youngs, M. Johnson et al. 1982. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br. J. Surg. 69: 137-139.
77. Pillai, A. & R. Nelson 2008. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database. Syst. Rev. (1): CD004611.
78. Miller, M. 2009. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 15: 281-284.
79. Snydman, D.R. 2008. The safety of probiotics. Clin. Infect. Dis. 46(Suppl. 2): S104-S111; discussioin S144-S151.
80. Aas, J., C.E. Gessert & J.S. Bakken 2003. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36: 580-585.
81. Yoon, S.S. & L.J. Brandt 2010. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J. Clin. Gastroenterol. 44: 562-566.
82. Bakken, J.S. 2009. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15: 295-299.
83. Silverman, M.S., I. Davis & D.R. Pillai 2010. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 8: 471-473.